MMV Supported Projects, 2Q 2015 Research Translational Translational Lead optimisationLead Lead generation Preclinical Preclinical Human volunteers Phase I Human Development Development Patient exploratory Phase IIa Patient Patient confirmatory Phase IIb/III Patient Access In registration Registration Phase Post IV approval optimisation Preclinical Miniportfolio 1 Project P218 MMV048 OZ439/PQP Tafenoquine Rectal Artesunate Novartis Novartis BIOTEC UCT/TIA Sanofi GSK CIPLA/Strides/TDR DHA-Piperaquine Paediatric PyronaridineArtesunate Paediatric ArtemetherLumefantrine Dispersible Shin Poong Novartis volunteers exploratory OZ439/FQ Miniportfolio 3 Projects SJ733 GSK GSK St Jude/Eisai Miniportfolio Orthologue Leads DDD498 Sanofi Sanofi Heterocycles Oxaboroles PA92 KAF156 Anacor (Drexel/UW/GNF) Novartis Sanofi confirmatory Under review * Sigma-Tau Celgene Heterocycles Campinas Heterocycles Daiichi-Sankyo Screening Takeda Merck Serono (Dundee) KAE609 Novartis Tetraoxanes MMV253 DSM265 LSTM/Liverpool (AstraZeneca) Takeda DHODH GSK030 GSK Aminopyridines UCT Eisai Sydney DSM421 (UTSW/UW/ Monash) Included in.
Download ReportTranscript MMV Supported Projects, 2Q 2015 Research Translational Translational Lead optimisationLead Lead generation Preclinical Preclinical Human volunteers Phase I Human Development Development Patient exploratory Phase IIa Patient Patient confirmatory Phase IIb/III Patient Access In registration Registration Phase Post IV approval optimisation Preclinical Miniportfolio 1 Project P218 MMV048 OZ439/PQP Tafenoquine Rectal Artesunate Novartis Novartis BIOTEC UCT/TIA Sanofi GSK CIPLA/Strides/TDR DHA-Piperaquine Paediatric PyronaridineArtesunate Paediatric ArtemetherLumefantrine Dispersible Shin Poong Novartis volunteers exploratory OZ439/FQ Miniportfolio 3 Projects SJ733 GSK GSK St Jude/Eisai Miniportfolio Orthologue Leads DDD498 Sanofi Sanofi Heterocycles Oxaboroles PA92 KAF156 Anacor (Drexel/UW/GNF) Novartis Sanofi confirmatory Under review * Sigma-Tau Celgene Heterocycles Campinas Heterocycles Daiichi-Sankyo Screening Takeda Merck Serono (Dundee) KAE609 Novartis Tetraoxanes MMV253 DSM265 LSTM/Liverpool (AstraZeneca) Takeda DHODH GSK030 GSK Aminopyridines UCT Eisai Sydney DSM421 (UTSW/UW/ Monash) Included in.
MMV Supported Projects, 2Q 2015 Research Translational Translational Lead optimisationLead Lead generation Preclinical Preclinical Human volunteers Phase I Human Development Development Patient exploratory Phase IIa Patient Patient confirmatory Phase IIb/III Patient Access In registration Registration optimisation Preclinical Miniportfolio 1 Project P218 MMV048 OZ439/PQP Tafenoquine Rectal Artesunate Novartis Novartis BIOTEC UCT/TIA Sanofi GSK CIPLA/Strides/TDR Miniportfolio GSK 3 Projects volunteers SJ733 exploratory OZ439/FQ Sanofi GSK St Jude/Eisai Miniportfolio Orthologue Leads DDD498 Sanofi Sanofi Heterocycles Oxaboroles PA92 KAF156 Anacor (Drexel/UW/GNF) Novartis confirmatory Under review * DHA-Piperaquine Paediatric Sigma-Tau Celgene Heterocycles Campinas Heterocycles Daiichi-Sankyo Screening Takeda Merck Serono (Dundee) KAE609 Novartis Tetraoxanes MMV253 DSM265 LSTM/Liverpool (AstraZeneca) Takeda DHODH GSK030 UTSW/UW/Monash GSK Aminopyridines UCT Sydney DSM421 (UTSW/UW/ Monash) Included in MMV portfolio post approval 15 Projects PyronaridineArtesunate Paediatric Shin Poong Novartis 2 DHA-Piperaquine Sigma-Tau 3 PyronaridineArtesunate Artesunate Amodiaquine 4 5 ArtesunateMefloquine CIPLA/DNDi Eisai Other Projects 1 Guilin ArtemetherLumefantrine Dispersible Sanofi/DNDi Open Source Drug Discovery MMV Artesunate for injection Shin Poong Screening Pathogen Box Phase Post IV approval Amino-alcohols Merck Serono * First review or approval by WHO Prequalification, or by regulatory bodies who are ICH members or observers 1 Brand 2 Brand 3 Brand 4 Brand 5 Brand 6 Brand name: Artesun® name: Coartem® Dispersible name: Eurartesim® name: Pyramax® names: CoarsucamTM, ASAQ/Winthrop® name: SPAQ-CO SulfadoxinePyrimethamine+ Amodiaquine 6 Guilin